



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/764433/2015

European Medicines Agency decision

P/0288/2015

of 27 November 2015

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (ABT-494) (EMA-001741-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0288/2015

of 27 November 2015

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (ABT-494) (EMA-001741-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by AbbVie Ltd on 13 February 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 October 2015, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (ABT-494), age-appropriate oral solid dosage form, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (ABT-494), age-appropriate oral solid dosage form, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (ABT-494), age-appropriate oral solid dosage form, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Business Park, Vanwall Road, SL6 4UB - Maidenhead, United Kingdom.

Done at London, 27 November 2015

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/501119/2015
London, 9 October 2015

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001741-PIP01-14

Scope of the application

Active substance(s):

(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (ABT-494)

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

Pharmaceutical form(s):

Age-appropriate oral solid dosage form

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted for agreement to the European Medicines Agency on 13 February 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 11 August 2015.

Supplementary information was provided by the applicant on 6 July 2015.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- tablet, age-appropriate oral dosage form; oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of juvenile idiopathic arthritis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate oral solid dosage form

Tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of age-appropriate oral solid dosage form; dispersible tablet or multi-particulate granules.
Non-clinical studies	2	Study 2 Dose range-finding juvenile toxicity study Study 3

Area	Number of measures	Description
		Definitive juvenile toxicity study to evaluate toxicity and impact of ABT-494 on neonatal/juvenile development.
Clinical studies	3	Study 4 Open-label, multiple dose study to evaluate the pharmacokinetics, safety, and tolerability and to confirm the dosing regimen of ABT-494 in children with active polyarticular course JIA Study 5 Randomised, placebo-controlled, double-blind withdrawal study to evaluate the safety and efficacy of ABT-494 in children with active polyarticular course JIA Study 6 Randomised, placebo-controlled, double-blind withdrawal study to evaluate the safety and efficacy of multiple doses of ABT-494 in children with active systemic JIA
Extrapolation, modelling and simulation studies	1	Study 7 Population pharmacokinetic two compartment model that characterizes the pharmacokinetic parameters, the inter- and intra-subject variability, and relationship between pharmacokinetic parameters and the relevant covariates
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes